Transcript Discovering and Developing New Medicines from Marine Microbes

Marine Technology Summit
November 16, 2010
Nereus Pharmaceuticals
Discovering and Developing
New Medicines from Marine Microbes
Ken Lloyd, Ph.D.
Chief Scientific Officer
1
Marine Technology Summit
November 16, 2010
Marine Microbiology: Paths to Success
Natural Product
•Mother Nature best
chemist
Marizomib (NPI-0052)
•Better characteristics than
>60 analogs
•Late Phase 1
•Multiple Myeloma
•Lymphomas
Derivative of Natural
Product
•Analogue Chemistry
•Precursor Manipulation
•Gene Strategies
Plinabulin (NPI-2358)
•Better profile than >200
analogs
•Late Phase 2
•Non small cell lung cancer
•Other solid tumors
2
Marizomib: Second Generation Proteasome
Inhibitor with Best-in-Class Properties
Marizomib (NPI-0052)
Key Points
 Unique structure as compared to synthetic
H
H
OH
H
N
O
O
O
H
CH3
Cl
•5 chiral centers
•17-step
chemical
synthesis
•1-step
fermentation
competitors
 Potent, broad spectrum proteasome inhibitor
 Highly selective for proteasome activities as
compared to other proteases
 Marizomib has commercially relevant benefits
secondary to unique structure

Superior safety profile

Superior efficacy (Velcade resistant tumors)

Potential for oral, sc, or sublingual
 Significant market opportunity in validated
indications with considerable upside in other
large market indications
3
Marizomib: Clinical Summation
 Excellent clinical safety profile with high levels of
proteasome inhibition
 Excellent pharmacodynamic results translating
from bench to clinic
 Proof of mechanism milestone achieved
 Anti-tumor activity seen in clinical trials
4
Cutaneous Marginal Zone Lymphoma Patient
Treated with Marizomib Weekly at 0.7 mg/m2
Baseline
Prior Treatments (2006-2009):
 Hyper-CVAD
 ASCT (Bu-MEL)
 XRT (TSEB & IF)
 Rituximab
Cycle 4 Day 22
Complete Response – Biopsy Confirmed
Continued Complete Response Cycle 4 through Cycle 15
5
Plinabulin: A Novel, Potent and Highly Selective
VDA with First-in-Class Potential
Plinabulin; NPI-2358
Themes
 On track to be the next major advance in
the treatment of multiple cancers after
success of angiogenesis inhibitors
O
N
HN
H
N
NH
O
•one of >250 analogues of
the natural product
•Potency >40 fold natural
product
•Straightforward
synthesis
 Major improvements over:

Anti-angiogenesis agents

Anti-microtubule cytotoxic agents
 Unique safety and efficacy profiles,
synergy and utility in unmet need
populations
 Novel plinabulin structure likely
responsible for advantages

Significantly improved safety profile

Potent and selective vascular disruption +
direct apoptotic effect to improve efficacy
6
Plinabulin: Clinical Summation
 Excellent clinical safety profile vs other VDAs and
other approved oncology drugs
 CNS/Neurological
 Cardiac
 Decreases docetaxel induced neutropenia
 Major adverse effect of docetaxel, a major chemotherapeutic
in the treatment of NSCLC
 Exceptional pharmacodynamic results (decrease in
tumor blood flow)
 Single agent clinical benefit rate of 30% in solid
tumors
 Durable;
up to 2 years
 Impressive early signal in 2nd line NSCLC study
7
Marine Technology Summit
November 16, 2010
Other low-hanging fruit for drug discovery from
marine microbiology
 Antiinfectives
 Major
antibiotic discovery effort ongoing at
SIO/UCSD
 Antifungals
 Antivirals
 Metabolic diseases, cardiovascular diseases
8
Thank you!
9